← BackIambic Therapeutics, Inc. · BiotechIAM
Low riskNext report: Not enough history
The short versionA company. Insiders are buying.
Watch out for
- 3 offering filings in 6 months (may sell new shares)
Money moves
- An insider bought $11.5M of shares with their own money in the last 30 days
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$14.40+2.1% that day
Latest insider buy: A director bought at $16.00 on Oct 16. The stock is now $14.40, -10.0% since.
From IAM's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
Insider rating
Last 90 days
82Strong buying
- 1 insider bought $11.5M
- Evan Lockwood Rachlin grew their stake 38.4%
50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.
Weekly insider trend13 weeks agoBoughtSoldThis week
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 3.1
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Why low risk- 3 offering filings in 6 months (may sell new shares)
Next reportNot enough history
Insider trades
Open-market buys and sells, last 90 days Bought$11.5M1 insider
Sold$00 insiders
| Insider | Trade | Shares | Avg price | Value | Owns after | Date |
|---|
Evan Lockwood RachlinDirector | Buy | 719K | $16.00 | $11.5M | 3M | |
- +38.4% of their holdings
- Held See footnote
- Filed 3 days after
|
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
BoughtEvan Lockwood RachlinDirector
718,750 shares at $16.00 · $11.5M
- +38% of holdings
- Now owns 2,588,248 shares
- Held See footnote
- Filed 3 days after trade
- Also: Conversion
ConversionWilliam H RastetterDirector
200,920 shares
- Now owns 200,920 shares
- Held See footnote
- 2 transactions
- Filed 3 days after trade
ConversionMichael SecoraCFO & Chief Corp Dev Ofcr
61,342 shares
- +28% of holdings
- Now owns 279,902 shares
- Filed 3 days after trade
ConversionR Jacob VogelsteinDirector
4,196,585 shares
- Now owns 742,546 shares
- Held See footnote
- 3 transactions
- Filed 3 days after trade
ConversionCatalio Capital Management, LP10% owner
4,196,585 shares
- Now owns 742,546 shares
- Held See footnote
- 3 transactions
- Filed 3 days after trade
- Joint filing with 4 others
Stock awardThomas F. MillerChief Executive Officer, Director
132,200 shares
- +10% of holdings
- Now owns 1,410,756 shares
- Exercise price $16.00
- Filed 2 days after trade
Stock awardFrederick R ManbyChief Technology Officer, Director
132,200 shares
- +8% of holdings
- Now owns 1,862,665 shares
- Exercise price $16.00
- Filed 2 days after trade
Stock awardNeil JosephsonChief Medical Officer
31,000 shares
- +77% of holdings
- Now owns 71,459 shares
- Exercise price $16.00
- Filed 2 days after trade
Stock awardPeter A OlsonChief Scientific Officer
19,500 shares
- +171% of holdings
- Now owns 30,909 shares
- Exercise price $16.00
- Filed 2 days after trade
Stock awardMichael SecoraCFO & Chief Corp Dev Ofcr
28,400 shares
- +15% of holdings
- Now owns 218,560 shares
- Exercise price $16.00
- Filed 2 days after trade
Stock awardEvan Lockwood RachlinDirector
20,300 shares
- Now owns 20,300 shares
- Exercise price $16.00
- Stock Option (right to buy)
- Filed 2 days after trade
Stock awardWilliam H RastetterDirector
40,600 shares
- Now owns 40,600 shares
- Exercise price $16.00
- Stock Option (right to buy)
- Filed 2 days after trade
Stock awardShalini SharpDirector
20,300 shares
- Now owns 20,300 shares
- Exercise price $16.00
- Stock Option (right to buy)
- Filed 2 days after trade
Stock awardMary TagliaferriDirector
20,300 shares
- Now owns 20,300 shares
- Exercise price $16.00
- 10/14/2026
- Filed 2 days after trade
Stock awardR Jacob VogelsteinDirector, 10% owner
20,300 shares
- Now owns 20,300 shares
- Exercise price $16.00
- Stock Option (right to buy)
- Filed 2 days after trade